JP7575183B2 - 吸入可能なニコチン製剤、ならびにその作製方法および使用方法 - Google Patents

吸入可能なニコチン製剤、ならびにその作製方法および使用方法 Download PDF

Info

Publication number
JP7575183B2
JP7575183B2 JP2018514451A JP2018514451A JP7575183B2 JP 7575183 B2 JP7575183 B2 JP 7575183B2 JP 2018514451 A JP2018514451 A JP 2018514451A JP 2018514451 A JP2018514451 A JP 2018514451A JP 7575183 B2 JP7575183 B2 JP 7575183B2
Authority
JP
Japan
Prior art keywords
nicotine
acid
particles
formulation
another embodiment
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2018514451A
Other languages
English (en)
Japanese (ja)
Other versions
JP2018528966A5 (enExample
JP2018528966A (ja
Inventor
アレックス シュテンツラー
ノエ ザメル
アーサー スルツキー
スティーヴン エリス
Original Assignee
フィリップ・モーリス・プロダクツ・ソシエテ・アノニム
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by フィリップ・モーリス・プロダクツ・ソシエテ・アノニム filed Critical フィリップ・モーリス・プロダクツ・ソシエテ・アノニム
Publication of JP2018528966A publication Critical patent/JP2018528966A/ja
Publication of JP2018528966A5 publication Critical patent/JP2018528966A5/ja
Priority to JP2022077936A priority Critical patent/JP2022097639A/ja
Priority to JP2024065173A priority patent/JP2024086897A/ja
Application granted granted Critical
Publication of JP7575183B2 publication Critical patent/JP7575183B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A24—TOBACCO; CIGARS; CIGARETTES; SIMULATED SMOKING DEVICES; SMOKERS' REQUISITES
    • A24B—MANUFACTURE OR PREPARATION OF TOBACCO FOR SMOKING OR CHEWING; TOBACCO; SNUFF
    • A24B15/00—Chemical features or treatment of tobacco; Tobacco substitutes, e.g. in liquid form
    • A24B15/10—Chemical features of tobacco products or tobacco substitutes
    • A24B15/16—Chemical features of tobacco products or tobacco substitutes of tobacco substitutes
    • A—HUMAN NECESSITIES
    • A24—TOBACCO; CIGARS; CIGARETTES; SIMULATED SMOKING DEVICES; SMOKERS' REQUISITES
    • A24B—MANUFACTURE OR PREPARATION OF TOBACCO FOR SMOKING OR CHEWING; TOBACCO; SNUFF
    • A24B15/00—Chemical features or treatment of tobacco; Tobacco substitutes, e.g. in liquid form
    • A24B15/18—Treatment of tobacco products or tobacco substitutes
    • A—HUMAN NECESSITIES
    • A24—TOBACCO; CIGARS; CIGARETTES; SIMULATED SMOKING DEVICES; SMOKERS' REQUISITES
    • A24B—MANUFACTURE OR PREPARATION OF TOBACCO FOR SMOKING OR CHEWING; TOBACCO; SNUFF
    • A24B15/00—Chemical features or treatment of tobacco; Tobacco substitutes, e.g. in liquid form
    • A24B15/18—Treatment of tobacco products or tobacco substitutes
    • A24B15/28—Treatment of tobacco products or tobacco substitutes by chemical substances
    • A24B15/30—Treatment of tobacco products or tobacco substitutes by chemical substances by organic substances
    • A24B15/36—Treatment of tobacco products or tobacco substitutes by chemical substances by organic substances containing a heterocyclic ring
    • A24B15/40—Treatment of tobacco products or tobacco substitutes by chemical substances by organic substances containing a heterocyclic ring having only oxygen or sulfur as hetero atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/045—Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
    • A61K31/198—Alpha-amino acids, e.g. alanine or edetic acid [EDTA]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/465—Nicotine; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A61K36/53—Lamiaceae or Labiatae (Mint family), e.g. thyme, rosemary or lavender
    • A61K36/534—Mentha (mint)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/007—Pulmonary tract; Aromatherapy
    • A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
    • A61K9/0075—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy for inhalation via a dry powder inhaler [DPI], e.g. comprising micronized drug mixed with lactose carrier particles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
    • A61K9/145—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with organic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
    • A61K9/148—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with compounds of unknown constitution, e.g. material from plants or animals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/14—Antitussive agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/34—Tobacco-abuse

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pulmonology (AREA)
  • Natural Medicines & Medicinal Plants (AREA)
  • Otolaryngology (AREA)
  • Addiction (AREA)
  • Organic Chemistry (AREA)
  • Botany (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Toxicology (AREA)
  • Mycology (AREA)
  • Neurology (AREA)
  • Zoology (AREA)
  • Biomedical Technology (AREA)
  • Alternative & Traditional Medicine (AREA)
  • Biotechnology (AREA)
  • Medical Informatics (AREA)
  • Microbiology (AREA)
  • Neurosurgery (AREA)
  • Psychiatry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Manufacture Of Tobacco Products (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
JP2018514451A 2015-09-16 2016-09-15 吸入可能なニコチン製剤、ならびにその作製方法および使用方法 Active JP7575183B2 (ja)

Priority Applications (2)

Application Number Priority Date Filing Date Title
JP2022077936A JP2022097639A (ja) 2015-09-16 2022-05-11 吸入可能なニコチン製剤、ならびにその作製方法および使用方法
JP2024065173A JP2024086897A (ja) 2015-09-16 2024-04-15 吸入可能なニコチン製剤、ならびにその作製方法および使用方法

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US14/856,102 2015-09-16
US14/856,102 US9585835B1 (en) 2015-09-16 2015-09-16 Inhalable nicotine formulations and methods of making and using the same
PCT/US2016/051963 WO2017048974A1 (en) 2015-09-16 2016-09-15 Inhalable nicotine formulations, and methods of making and using thereof

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2022077936A Division JP2022097639A (ja) 2015-09-16 2022-05-11 吸入可能なニコチン製剤、ならびにその作製方法および使用方法

Publications (3)

Publication Number Publication Date
JP2018528966A JP2018528966A (ja) 2018-10-04
JP2018528966A5 JP2018528966A5 (enExample) 2019-10-17
JP7575183B2 true JP7575183B2 (ja) 2024-10-29

Family

ID=58162192

Family Applications (3)

Application Number Title Priority Date Filing Date
JP2018514451A Active JP7575183B2 (ja) 2015-09-16 2016-09-15 吸入可能なニコチン製剤、ならびにその作製方法および使用方法
JP2022077936A Pending JP2022097639A (ja) 2015-09-16 2022-05-11 吸入可能なニコチン製剤、ならびにその作製方法および使用方法
JP2024065173A Pending JP2024086897A (ja) 2015-09-16 2024-04-15 吸入可能なニコチン製剤、ならびにその作製方法および使用方法

Family Applications After (2)

Application Number Title Priority Date Filing Date
JP2022077936A Pending JP2022097639A (ja) 2015-09-16 2022-05-11 吸入可能なニコチン製剤、ならびにその作製方法および使用方法
JP2024065173A Pending JP2024086897A (ja) 2015-09-16 2024-04-15 吸入可能なニコチン製剤、ならびにその作製方法および使用方法

Country Status (19)

Country Link
US (1) US9585835B1 (enExample)
EP (1) EP3349599B1 (enExample)
JP (3) JP7575183B2 (enExample)
KR (1) KR102760317B1 (enExample)
CN (1) CN106539794B (enExample)
AU (1) AU2016323317A1 (enExample)
BR (1) BR112018005145B1 (enExample)
CA (1) CA2999082A1 (enExample)
ES (1) ES2997334T3 (enExample)
HK (1) HK1258016A1 (enExample)
IL (1) IL258143A (enExample)
MX (1) MX394985B (enExample)
MY (1) MY184362A (enExample)
PH (1) PH12018500544A1 (enExample)
PL (1) PL3349599T3 (enExample)
RU (1) RU2719228C2 (enExample)
UA (1) UA126849C2 (enExample)
WO (1) WO2017048974A1 (enExample)
ZA (1) ZA201801569B (enExample)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9968125B2 (en) * 2015-01-09 2018-05-15 Philip Morris Products S.A. Nicotine—diketopiperazine microparticle formulations and methods of making the same
US11224594B2 (en) * 2015-09-16 2022-01-18 Philip Morris Products S.A. Nicotine formulations and methods of making and using the same
US10149844B2 (en) 2015-09-16 2018-12-11 Philip Morris Products S.A. Inhalable nicotine formulations, and methods of making and using thereof
MX385972B (es) * 2016-06-30 2025-03-18 Philip Morris Products Sa Partículas y composiciones de nicotina.
JP7680823B2 (ja) * 2017-03-07 2025-05-21 フィリップ・モーリス・プロダクツ・ソシエテ・アノニム 吸入可能なニコチン製剤、およびその作製および使用方法
WO2019003118A1 (en) 2017-06-28 2019-01-03 Philip Morris Products S.A. CONTAINER WITH PARTICLES FOR USE WITH INHALER
GB201817868D0 (en) * 2018-11-01 2018-12-19 Nicoventures Trading Ltd Aerosolised formulation
GB201817862D0 (en) 2018-11-01 2018-12-19 Nicoventures Trading Ltd Aerosolisable formulation
WO2021094160A1 (en) * 2019-11-14 2021-05-20 Philip Morris Products S.A. Improved tobacco flavoured dry powder formulation
CN115697299A (zh) * 2020-06-15 2023-02-03 菲利普莫里斯生产公司 新烟草碱粉末组合物
JP2023540190A (ja) 2020-09-03 2023-09-22 フィリップ・モーリス・プロダクツ・ソシエテ・アノニム 低吸湿性活性粉末組成物
US20220313678A1 (en) * 2021-04-06 2022-10-06 Altria Client Services Llc Spray dried nicotine for inclusion in oral products
US20220313614A1 (en) * 2021-04-06 2022-10-06 Altria Client Services Llc Encapsulated nicotine granules and methods of preparation thereof
CN120500327A (zh) * 2022-10-27 2025-08-15 韩国烟草人参公社 用于吸入的低剂量尼古丁干粉组合物
CN120417888A (zh) * 2022-10-27 2025-08-01 韩国烟草人参公社 用于吸入的尼古丁干粉的制备方法
CN117158443B (zh) * 2023-09-05 2024-03-22 贵州大学 烟碱在制备贝莱斯芽胞杆菌生防作用增强剂中的应用

Citations (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2002506017A (ja) 1998-03-11 2002-02-26 スラトスキー．アート ニコチン吸入器
JP2002161030A (ja) 2000-11-27 2002-06-04 Unisia Jecs Corp 異なる粒径をもった混合粉体の吸入方法
JP2003519175A (ja) 1999-12-30 2003-06-17 カイロン コーポレイション インターロイキン−２の肺送達のための方法
JP2004515467A (ja) 2000-08-07 2004-05-27 ネクター セラピューティックス 吸入可能な、噴霧乾燥した、最少の凝集物を有する４−ヘリックスバンドルタンパク質粉末
JP2006522634A (ja) 2003-04-14 2006-10-05 ベクトゥラ・リミテッド 投与効率を向上させるデバイス及び製薬組成
JP2007505037A (ja) 2003-09-08 2007-03-08 ファイザー・ヘルス・アクティエボラーグ ニコチン製剤およびその使用
US20090068276A1 (en) 2007-05-22 2009-03-12 Vectura Group Plc Pharmaceutical compositions
JP2009519972A (ja) 2005-12-15 2009-05-21 アキュスフィア， インコーポレイテッド 粒子ベースの経肺投与または経鼻投与用製薬の製造方法
JP2010531188A (ja) 2007-06-25 2010-09-24 カインド・コンシューマー・リミテッド 吸入可能な組成物
JP2013528588A (ja) 2010-05-07 2013-07-11 ニコノバム・ユー・エス・エイ・インコーポレイテツド ニコチン含有医薬組成物
JP2014522880A (ja) 2011-08-08 2014-09-08 プロソニックス リミテッド 製剤組成物

Family Cites Families (44)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5441060A (en) * 1993-02-08 1995-08-15 Duke University Dry powder delivery system
CA2146954C (en) 1995-04-12 2008-06-17 Arthur Slutsky Breath activated nicotine inhalers
AUPN862596A0 (en) * 1996-03-12 1996-04-04 F.H. Faulding & Co. Limited Pharmaceutical compositions
CN1110271C (zh) * 1997-09-22 2003-06-04 株式会社大城 烟草调味剂及其烟草
US20120042886A1 (en) 1998-03-11 2012-02-23 Hanna Piskorz Method of producing a nicotine medicament and a medicament made by the method
CA2265198C (en) 1998-03-11 2009-01-27 Zamel, Noe Method of producing a nicotine medicament and a medicament made by the method
US6234169B1 (en) 1998-08-14 2001-05-22 Arthur Slutsky Inhaler
ES2395096T3 (es) 1999-06-29 2013-02-08 Mannkind Corporation Purificación y estabilización de agentes farmacéuticos a base de péptidos y proteínas
US8256433B2 (en) 1999-07-16 2012-09-04 Aradigm Corporation Systems and methods for effecting cessation of tobacco use
US6799576B2 (en) 1999-07-16 2004-10-05 Aradigm Corporation System for effecting smoking cessation
US6586008B1 (en) * 1999-08-25 2003-07-01 Advanced Inhalation Research, Inc. Use of simple amino acids to form porous particles during spray drying
US7871598B1 (en) 2000-05-10 2011-01-18 Novartis Ag Stable metal ion-lipid powdered pharmaceutical compositions for drug delivery and methods of use
FR2815987B1 (fr) 2000-10-27 2003-02-28 Michel Petiot Embase enfichable pour poteau ou piquet
ITMI20012174A1 (it) * 2001-10-18 2003-04-18 Univ Parma Polvere per somministrazione nasale di farmaci
EP1578422B1 (en) 2002-12-20 2007-04-11 NicoNovum AB A physically and chemically stable nicotine and micorcrystalline cellulose containing particulate material
WO2005000267A2 (en) 2003-05-28 2005-01-06 Nektar Therapeutics Spray drying of an alcoholic aqueous solution for the manufacture of a water-insoluble active agentmicroparticle with a partial or complete amino acid and/or phospholipid coat
GB0321607D0 (en) * 2003-09-15 2003-10-15 Vectura Ltd Manufacture of pharmaceutical compositions
SE528121C2 (sv) * 2004-03-29 2006-09-05 Mederio Ag Preparering av torrpulver för på förhand uppmätt DPI
GB0410398D0 (en) 2004-05-10 2004-06-16 Arakis Ltd The treatment of respiratory disease
ATE553074T1 (de) * 2004-05-24 2012-04-15 British American Tobacco Co Molekular geprägte, nitrosaminselektive polymere und verfahren zu deren anwendung
GB0425758D0 (en) * 2004-11-23 2004-12-22 Vectura Ltd Preparation of pharmaceutical compositions
NZ564025A (en) * 2005-05-11 2012-03-30 Vector Tobacco Inc Reduced risk tobacco products and methods of making same
GB0523576D0 (en) * 2005-11-18 2005-12-28 Theradeas Ltd Drug composition and its use in therapy
CA2648291A1 (en) 2006-04-04 2007-11-01 Stc.Unm Swellable particles for drug delivery
FI20060428L (fi) * 2006-05-03 2007-11-04 Esko Kauppinen Pintamodifioidut aerosolihiukkaset, menetelmä ja laite niiden tuottamiseksi sekä jauheet ja dispersiot jotka sisältävät kyseisiä hiukkasia
EP2086317A4 (en) * 2006-12-01 2010-03-03 Aradigm Corp NICOTINE FORMULATIONS, KITS AND SYSTEMS AND METHOD FOR THEIR USE
GB0801876D0 (en) * 2008-02-01 2008-03-12 Vectura Group Plc Suspension formulations
GB0905840D0 (en) * 2009-04-06 2009-05-20 Sagentia Ltd Apparatus and methods
US20110268809A1 (en) 2010-04-28 2011-11-03 Paul Andrew Brinkley Nicotine-Containing Pharmaceutical Compositions
US20130017259A1 (en) * 2011-07-06 2013-01-17 The Parkinson's Institute Compositions and Methods for Treatment of Symptoms in Parkinson's Disease Patients
RS58456B1 (sr) * 2011-08-01 2019-04-30 Univ Monash Postupak i formulacije za inhalaciju
US9907748B2 (en) 2011-10-21 2018-03-06 Niconovum Usa, Inc. Excipients for nicotine-containing therapeutic compositions
US20130177646A1 (en) 2012-01-05 2013-07-11 Mcneil Ab Solid Nicotine-Comprising Dosage Form with Reduced Organoleptic Disturbance
US9763928B2 (en) 2012-02-10 2017-09-19 Niconovum Usa, Inc. Multi-layer nicotine-containing pharmaceutical composition
US9056057B2 (en) 2012-05-03 2015-06-16 Kala Pharmaceuticals, Inc. Nanocrystals, compositions, and methods that aid particle transport in mucus
GB201215273D0 (en) * 2012-08-28 2012-10-10 Kind Consumer Ltd Nicotine composition
US20140088045A1 (en) * 2012-09-21 2014-03-27 Basil Rigas Product comprising a nicotine-containing material and an anti-cancer agent
US20140166027A1 (en) 2012-12-14 2014-06-19 Richard C. Fuisz Enhanced Delivery of Nicotine, THC, Tobacco, Cannabidiol or Base Alkaloid from an Electronic Cigarette or Other Vapor Producing Device Through Use of an Absorption Conditioning Unit
US20140261474A1 (en) 2013-03-15 2014-09-18 Aradigm Corporation Methods for inhalation of smoke-free nicotine
KR20190075168A (ko) * 2014-04-08 2019-06-28 필립모리스 프로덕츠 에스.에이. 니코틴 제형 및 이의 제조방법
CA2943459C (en) 2014-04-28 2023-05-02 Philip Morris Products S.A. Nicotine powder inhaler
CN106170313B (zh) 2014-04-28 2020-11-10 菲利普莫里斯生产公司 带香味尼古丁粉末吸入器
FR3035826B1 (fr) * 2015-05-07 2018-11-16 Saint-Gobain Glass France Vitrage de vehicule comprenant une platine pour la fixation de plusieurs accessoires, platine et procede de fixation.
US11224594B2 (en) * 2015-09-16 2022-01-18 Philip Morris Products S.A. Nicotine formulations and methods of making and using the same

Patent Citations (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2002506017A (ja) 1998-03-11 2002-02-26 スラトスキー．アート ニコチン吸入器
JP2003519175A (ja) 1999-12-30 2003-06-17 カイロン コーポレイション インターロイキン−２の肺送達のための方法
JP2004515467A (ja) 2000-08-07 2004-05-27 ネクター セラピューティックス 吸入可能な、噴霧乾燥した、最少の凝集物を有する４−ヘリックスバンドルタンパク質粉末
JP2002161030A (ja) 2000-11-27 2002-06-04 Unisia Jecs Corp 異なる粒径をもった混合粉体の吸入方法
JP2006522634A (ja) 2003-04-14 2006-10-05 ベクトゥラ・リミテッド 投与効率を向上させるデバイス及び製薬組成
JP2007505037A (ja) 2003-09-08 2007-03-08 ファイザー・ヘルス・アクティエボラーグ ニコチン製剤およびその使用
JP2009519972A (ja) 2005-12-15 2009-05-21 アキュスフィア， インコーポレイテッド 粒子ベースの経肺投与または経鼻投与用製薬の製造方法
US20090068276A1 (en) 2007-05-22 2009-03-12 Vectura Group Plc Pharmaceutical compositions
JP2010531188A (ja) 2007-06-25 2010-09-24 カインド・コンシューマー・リミテッド 吸入可能な組成物
JP2013528588A (ja) 2010-05-07 2013-07-11 ニコノバム・ユー・エス・エイ・インコーポレイテツド ニコチン含有医薬組成物
JP2014522880A (ja) 2011-08-08 2014-09-08 プロソニックス リミテッド 製剤組成物

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
Ｐｏｗｄｅｒ Ｔｅｃｈｎｏｌ．， ２０１１， Ｖｏｌ．２１４， ｐｐ．１６９－１７６

Also Published As

Publication number Publication date
PL3349599T3 (pl) 2025-03-24
CN106539794B (zh) 2020-05-15
PH12018500544A1 (en) 2018-09-24
EP3349599C0 (en) 2024-11-20
UA126849C2 (uk) 2023-02-15
US9585835B1 (en) 2017-03-07
MY184362A (en) 2021-04-01
AU2016323317A1 (en) 2018-04-12
US20170071856A1 (en) 2017-03-16
ZA201801569B (en) 2019-01-30
HK1258016A1 (zh) 2019-11-01
ES2997334T3 (en) 2025-02-17
MX394985B (es) 2025-03-24
CN106539794A (zh) 2017-03-29
EP3349599A1 (en) 2018-07-25
MX2018003272A (es) 2018-08-16
WO2017048974A1 (en) 2017-03-23
RU2018113460A3 (enExample) 2019-10-18
BR112018005145B1 (pt) 2022-05-03
EP3349599A4 (en) 2019-04-17
RU2018113460A (ru) 2019-10-18
IL258143A (en) 2018-05-31
JP2024086897A (ja) 2024-06-28
CA2999082A1 (en) 2017-03-23
KR20180077150A (ko) 2018-07-06
WO2017048974A8 (en) 2018-04-12
RU2719228C2 (ru) 2020-04-17
EP3349599B1 (en) 2024-11-20
KR102760317B1 (ko) 2025-02-03
JP2022097639A (ja) 2022-06-30
JP2018528966A (ja) 2018-10-04
BR112018005145A2 (pt) 2018-12-11

Similar Documents

Publication Publication Date Title
JP2024086897A (ja) 吸入可能なニコチン製剤、ならびにその作製方法および使用方法
US11707432B2 (en) System and method for controlling the harshness of nicotine-based dry powder formulations
JP7680823B2 (ja) 吸入可能なニコチン製剤、およびその作製および使用方法
KR102696600B1 (ko) 니코틴 제형, 및 이의 이용 및 제조방법
US10660883B2 (en) Inhalable nicotine formulations, and methods of making and using thereof

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20190903

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20190903

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20200713

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20201012

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20210301

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20210528

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20210730

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20210831

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20220111

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20220511

C60 Trial request (containing other claim documents, opposition documents)

Free format text: JAPANESE INTERMEDIATE CODE: C60

Effective date: 20220511

C11 Written invitation by the commissioner to file amendments

Free format text: JAPANESE INTERMEDIATE CODE: C11

Effective date: 20220523

A911 Transfer to examiner for re-examination before appeal (zenchi)

Free format text: JAPANESE INTERMEDIATE CODE: A911

Effective date: 20220627

C21 Notice of transfer of a case for reconsideration by examiners before appeal proceedings

Free format text: JAPANESE INTERMEDIATE CODE: C21

Effective date: 20220629

A912 Re-examination (zenchi) completed and case transferred to appeal board

Free format text: JAPANESE INTERMEDIATE CODE: A912

Effective date: 20220722

C211 Notice of termination of reconsideration by examiners before appeal proceedings

Free format text: JAPANESE INTERMEDIATE CODE: C211

Effective date: 20220727

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20231012

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20231113

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20240508

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20240607

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20240708

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20241017

R150 Certificate of patent or registration of utility model

Ref document number: 7575183

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150